Eikon Therapeutics filings document its transition to a Nasdaq-listed public company, its common stock registration, governance documents, financial results, and clinical and corporate updates. The company’s Form 8-K disclosures include results of operations and financial condition, exhibits containing press releases, and amendments to its certificate of incorporation and bylaws in connection with its initial public offering.
The filings also identify Eikon’s common stock, par value, trading symbol, Nasdaq listing, and public-company governance framework. For this clinical-stage biopharmaceutical issuer, regulatory disclosures center on capital structure, shareholder matters, clinical program updates, and corporate reporting obligations.
Eikon Therapeutics, Inc. is conducting an initial public offering of 21,177,600 shares of common stock at $18.00 per share, for a stated gross offering amount of $381,196,800 and estimated net proceeds to the company, before expenses, of $354,513,024. Underwriters have a 30‑day option to buy up to 3,176,640 additional shares at the same price, less underwriting discounts and commissions. The stock is approved for listing on the Nasdaq Global Select Market under the symbol “EIKN.”
Eikon is a late‑stage clinical biopharmaceutical company focused on oncology, with multiple product candidates in Phase 1/2 and Phase 2/3 trials, including toll‑like receptor and selective PARP1 inhibitors, a WRN helicase inhibitor, and androgen receptor programs. The company estimates cash, cash equivalents and short‑term investments of approximately $336.0 million as of December 31, 2025, but has reported recurring net losses of about $244.6 million for the nine months ended September 30, 2025 and an accumulated deficit of $840.9 million. Its own analysis notes substantial doubt about its ability to continue as a going concern without raising additional capital.